December 13, 2022
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer(Securities Code: 4582)

Presentation on the Anti-lymphoma Activity of Brincidofovirat the 64th ASH Annual Meeting
TOKYO, Japan, December 13, 2022 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo,"SymBio" or the “Company”) today announced that results of its research collaboration with theNational Cancer Centre Singapore (“NCCS”) on brincidofovir (“BCV") were presented by Dr. Jason
Yongsheng Chan at the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans.
This was the first announcement of the findings from a non-clinical study demonstrating that BCV
could be effective in the treatment of NK/T-cell lymphoma*1, a rapidly progressing form of lymphoma,
for which no effective treatment is available. During the study, BCV showed strong anti-lymphoma
activity compared to other existing antiviral agents, as most NK/T-cell lymphomas are known to be
Epstein-Barr virus (EBV)*2 positive. Furthermore, this study confirmed for the first time that BCV
suppressed both the expression of MYC*3, an oncogene that contributes to tumor malignancy, and theexpression of a dominant gene cluster, and that BCV induced immunogenic cell death which is known
to activate cancer immunity. In addition, BCV showed clear tumor growth inhibitory effect in a mousemodel in which the tumor was transplanted.
Dr. Jason Yongsheng Chan, Principal Investigator of the study, Consultant in the Division of Medical
Oncology, NCCS, and Clinical Assistant Professor at Duke-NUS Medical School said: “In this joint
research, the anti-tumor activity of BCV against NK/T-cell lymphoma was newly confirmed, and its
mechanism of action is very interesting. BCV has the potential to become a new therapeutic agent in
the field of oncology, including lymphoma.”
Mr. Fuminori Yoshida, President and Chief Executive Officer of SymBio said: “The anti-tumor effect ofBCV, confirmed by the results of this study, also suppresses factors that worsen the prognosis of tumor
diseases, including lymphoma, suggesting that BCV may be an option not only for EBV-positive
malignant lymphomas but also for a wide range of other diseases."
The Company does not anticipate the information presented herein to have any material impact on its
financial outlook for the fiscal year ending December 2022.
1

[Contact]
Investor Relations
Tel: +81 (0)3 5472 1125
(Note1) NK/T cell lymphoma
A type of malignant lymphoma that originates from NK or T cells. NK/T-cell lymphomas are classified
as low-grade (progressing yearly), intermediate-grade (progressing monthly), or high-grade(progressing weekly), and mainly present as extranodal NK/T-cell lymphomas in the perinasal space oron the skin. This disease is characterized by its relatively high prevalence in Southeast Asia, including
China.
(Note2) Epstein-Barr virus (EBV)The EBV is one of the human herpesvirus types and firstly investigated in the Burkitt lymphoma inchild, prevalent mainly in Africa, in 1964 as the oncogenic virus. Infection with EBV in childhood isusually asymptomatic or mild disease. When infection with EBV occurs during adolescence, it causes
infectious mononucleosis accompanied by transient fever, sore throat or lymphadenopathy. The causal
relationship of EBV with some malignant lymphoma, nasopharyngeal cancer and so on has beenclarified.
(Note3) MYC
Also known as c-Myc, is one of the oldest oncogenes, and abnormalities of this family of genes have beenfound in a wide range of cancer types, including translocations, mutations, and amplifications inhematopoietic tumors. It functions as a nuclear transcriptional regulator and is known to be a very
important factor that controls the balance of proliferation and differentiation of hematopoietic cells by
regulating the expression of dominant genes.
About anti-viral drug brincidofovir
Brincidofovir (BCV) is a lipid conjugate of cidofovir (CDV). CDV is an antiviral drug already approved
and marketed in the United States and the European Union, but unapproved in Japan. As BCV exhibits
not only higher anti-viral activity, but also a superior characteristics profile in comparison with CDV
and other antiviral drugs, BCV is expected to be an effective treatment against a wide spectrum ofdsDNA viruses such as herpesviruses such as cytomegalovirus (CMV), adenovirus (AdV), Epstein-Barrvirus (EBV), polyomaviruses and papillomavirus. Moreover, BCV is expected to be a highly active
antimultiviral agent that can reduce the risk of nephrotoxicity or myelosuppression, which are serious
side effects of other antiviral drugs including CDV.
The Company aims to expand its business to become a global specialty pharmaceutical company by2030. To maximize business value, the Company is currently conducting a global Phase II clinical trial
mainly in the U.S. for patients with adenovirus infection in immunocompromised conditions including2

after hematopoietic stem cell transplantation, and initiated a global Phase II clinical trial mainly inAustralia, Japan, and South Korea for patients with BK virus nephropathy after kidneytransplantation.
In addition to its high antiviral activity, BCV is also expected to have anti-tumor effects, and we are
currently conducting joint research with the National Cancer Center of Singapore, the University ofCalifornia, San Francisco, and Brown University in the U.S. to confirm BCV’s anti-cancer activity andsynergistic effects when combined with its antiviral activity. Furthermore, the Company has initiateda study to evaluate the potential antiviral activity of BCV against EBV in collaboration with theNational Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health(NIH) in the U.S.
About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who previouslyserved concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May
2016, the Company incorporated its wholly-owned subsidiary in the U.S., SymBio Pharma USA, Inc.
(Headquarters: Durham, North Carolina, President: Carolyn Yanavich).
The Company’s underlying corporate mission is to “deliver hope to patients in need” as it aspires to bea leading global specialty biopharmaceutical company dedicated to addressing underserved medicalneeds.

3